Literature DB >> 29493577

Mosaic maternal 10qter deletions are associated with FRA10B expansions and may cause false-positive noninvasive prenatal screening results.

Karin Huijsdens-van Amsterdam1, Roy Straver2, Merel C van Maarle1, Alida C Knegt1, Diane Van Opstal3, Frank Sleutels3, Dominique Smeets4, Erik A Sistermans5.   

Abstract

PURPOSE: Using genome-wide noninvasive prenatal screening (NIPS), we detected a 20-megabase specific deletion starting at 10q25 in eight pregnancies. The deletion could not be confirmed by invasive testing. Since all 10(q25→qter) deletions started close to the FRA10B fragile site in 10q25, we investigated whether the pregnant women were indeed carriers of FRA10B.
METHODS: We performed NIPS analysis for all autosomes using single-read sequencing. Analysis was done with the WISECONDOR algorithm. Culture of blood lymphocytes with bromodeoxyuridine was used to detect FRA10B expansions. Fluorescence in situ hybridization and array analysis were used to find maternal and/or fetal deletions.
RESULTS: We confirmed the presence of a FRA10B expansion in all four tested mothers. Fluorescence in situ hybridization and array analysis confirmed the presence of a maternal mosaic deletion of 10(q25→qter).
CONCLUSION: The recurring 10(q25→qter) deletion detected with NIPS is a false-positive result caused by a maternal low-level mosaic deletion associated with FRA10B expansions. This has important consequences for clinical follow-up, as invasive procedures are unnecessary. Expanded maternal FRA10B repeats should be added to the growing group of variants in the maternal genome that may cause false-positive NIPS results.

Entities:  

Keywords:  FRA10B; NIPS; false-positive results; fragile sites; noninvasive prenatal screening

Mesh:

Year:  2018        PMID: 29493577     DOI: 10.1038/gim.2018.32

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  4 in total

1.  WisecondorX: improved copy number detection for routine shallow whole-genome sequencing.

Authors:  Lennart Raman; Annelies Dheedene; Matthias De Smet; Jo Van Dorpe; Björn Menten
Journal:  Nucleic Acids Res       Date:  2019-02-28       Impact factor: 16.971

2.  TRIDENT-2: National Implementation of Genome-wide Non-invasive Prenatal Testing as a First-Tier Screening Test in the Netherlands.

Authors:  Karuna R M van der Meij; Erik A Sistermans; Merryn V E Macville; Servi J C Stevens; Caroline J Bax; Mireille N Bekker; Caterina M Bilardo; Elles M J Boon; Marjan Boter; Karin E M Diderich; Christine E M de Die-Smulders; Leonie K Duin; Brigitte H W Faas; Ilse Feenstra; Monique C Haak; Mariëtte J V Hoffer; Nicolette S den Hollander; Iris H I M Hollink; Fernanda S Jehee; Maarten F C M Knapen; Angelique J A Kooper; Irene M van Langen; Klaske D Lichtenbelt; Ingeborg H Linskens; Merel C van Maarle; Dick Oepkes; Mijntje J Pieters; G Heleen Schuring-Blom; Esther Sikkel; Birgit Sikkema-Raddatz; Dominique F C M Smeets; Malgorzata I Srebniak; Ron F Suijkerbuijk; Gita M Tan-Sindhunata; A Jeanine E M van der Ven; Shama L van Zelderen-Bhola; Lidewij Henneman; Robert-Jan H Galjaard; Diane Van Opstal; Marjan M Weiss
Journal:  Am J Hum Genet       Date:  2019-11-07       Impact factor: 11.025

3.  Initial Clinical Experience with NIPT for Rare Autosomal Aneuploidies and Large Copy Number Variations.

Authors:  Thomas Harasim; Teresa Neuhann; Anne Behnecke; Miriam Stampfer; Elke Holinski-Feder; Angela Abicht
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241

4.  Genome-wide cell-free DNA screening: a focus on copy-number variants.

Authors:  Jill Rafalko; Erica Soster; Samantha Caldwell; Eyad Almasri; Thomas Westover; Vivian Weinblatt; Philip Cacheris
Journal:  Genet Med       Date:  2021-06-21       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.